Indoleamine 2,3‑dioxygenase/IDO Immune Checkpoint Inhibitors

Indoleamine 2,3-dioxygenase (IDO) immune checkpoint inhibitors are cancer therapy drugs functioning on Indoleamine 2,3-dioxygenase (IDO), which is another category of immune-inhibitory molecules, and is expressed by both tumour cells and infiltrating myeloid cells. To enhance cancer therapy, Indoleamine 2,3-dioxygenase (IDO) immune checkpoint inhibitors: Indoximod and Ovarian Cancer, are developped for tumours, such as breast cancer and ovarian cancer.

Indoleamine 2,3-dioxygenase/IDO Immune Checkpoint Inhibitors: Developments

Disease Indoleamine 2,3-dioxygenase/IDO immune checkpoint inhibitors research development
Breast Cancer Indoximod —— a phase II trial of chemotherapy is conducted in combination with indoximod, an Indoleamine 2,3-dioxygenase/IDO immune checkpoint inhibitors drug, in metastatic breast cancer (NCT01792050).
Ovarian Cancer INCB024360 —— A pilot study was conducted to test INCB024360, an Indoleamine 2,3-dioxygenase/IDO immune checkpoint inhibitors drug, in patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer (NCT02042430).